Press releases
-
ICON announces pricing of USD 2 billion notes
Consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).
-
ICON reports first quarter 2024 results
Quarter one revenue of $2,090.4 million representing an increase of 5.7% on prior year revenue and 5.4% on a constant currency basis.
-
ICON announces CFO transition
ICON today announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry.
-
ICON plc schedules first quarter 2024 earnings conference call
Will hold a conference call and webcast to discuss its financial results and performance on 25 April, 2024.
-
ICON plc to present at upcoming investor conferences
Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024.
-
ICON reports fourth quarter and full year 2023 results
Full year net business wins of $9,946 million; a net book to bill of 1.22.
-
ICON plc schedules fourth quarter and full year 2023 earnings conference call
ICON announces that it will release its financial results for the fourth quarter and full year 2023 results after the market closes on Wednesday, February 21, 2024.
-
New ICON survey highlights importance of combination therapies in future obesity treatment
ICON announced results from a recent industry survey of over 100 professionals engaged in obesity-related clinical research to measure industry opinions on trends within this therapeutic area.
-
ICON issues financial guidance for full year 2024
ICON plc today announced its financial guidance for the year ending December 31, 2024.
-
Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON
ICON plc today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilise investment funding.
